{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:43:51Z","timestamp":1770331431521,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T00:00:00Z","timestamp":1660003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.msard.2022.104080","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T12:48:53Z","timestamp":1659012533000},"page":"104080","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Adherence and discontinuation rates in patients on Tecfidera\u2122 (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE\u2122 support program"],"prefix":"10.1016","volume":"67","author":[{"given":"Mattea Tan","family":"Thompson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devonshire","family":"Virginia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belviso","family":"Nick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillen","family":"Melissa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noella","family":"Engineer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Reedie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.104080_bib0001","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/1471-2377-13-138","article-title":"Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study","volume":"13","author":"Agashivala","year":"2013","journal-title":"BMC Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104080_bib0002","doi-asserted-by":"crossref","first-page":"37","DOI":"10.24095\/hpcdp.37.2.02","article-title":"Multiple sclerosis in Canada 2011 to 2031: results of a microsimulation modelling study of epidemiological and economic impacts","volume":"37","author":"Amankwah","year":"2017","journal-title":"Health Promot. Chronic Dis. Prev. Can."},{"key":"10.1016\/j.msard.2022.104080_bib0003","unstructured":"Biogen Canada Inc., 2013. Tecfidera\u2122 product monograph. https:\/\/www.biogen.ca\/content\/dam\/corporate\/en_CA\/pdfs\/products\/TECFIDERA\/TECFIDERA_PM_EN_07Oct2021.pdf (accessed 13 December 2021)."},{"issue":"7","key":"10.1016\/j.msard.2022.104080_bib0004","first-page":"770","article-title":"Patient support program increased medication adherence with lower total health care costs despite increased drug spending","volume":"25","author":"Brixner","year":"2019","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"2","key":"10.1016\/j.msard.2022.104080_bib0005","article-title":"Effect of dimethyl fumarate on lymphocyte subsets in patients with relapsing multiple sclerosis","volume":"6","author":"Buckle","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"issue":"1","key":"10.1016\/j.msard.2022.104080_bib0006","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210417","article-title":"A retrospective claims analysis: compliance and discontinuation rates among Canadian patients with multiple sclerosis treated with disease-modifying therapies","volume":"14","author":"Duquette","year":"2019","journal-title":"PLOS One"},{"issue":"5","key":"10.1016\/j.msard.2022.104080_bib0007","first-page":"639","article-title":"Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data","volume":"27","author":"Engmann","year":"2021","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"10.1016\/j.msard.2022.104080_bib0008","first-page":"711","article-title":"The impact of patient support programs on adherence, clinical, humanistic, and economic patient outcomes: a targeted systematic review","volume":"10","author":"Ganguli","year":"2016","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.msard.2022.104080_bib0009","article-title":"Long-term safety and efficacy of dimethyl fumarate for up to 13 years in patients with relapsing-remitting multiple sclerosis: final ENDORSE study results","author":"Gold","year":"2021","journal-title":"Mult. Scler."},{"issue":"2","key":"10.1016\/j.msard.2022.104080_bib0010","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3111\/13696998.2012.744316","article-title":"Assessing the role of patient support services on adherence rates in patients using glatiramer acetate for relapsing-remitting multiple sclerosis","volume":"16","author":"Jones","year":"2013","journal-title":"J. Med. Econ."},{"issue":"2","key":"10.1016\/j.msard.2022.104080_bib0011","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1017\/cjn.2015.325","article-title":"Canadian experience with fingolimod: adherence to treatment and monitoring","volume":"43","author":"Lapierre","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"issue":"15","key":"10.1016\/j.msard.2022.104080_bib0012","doi-asserted-by":"crossref","first-page":"e1724","DOI":"10.1212\/WNL.0000000000007262","article-title":"Effect of dimethyl fumarate on lymphocytes in RRMS: implications for clinical practice","volume":"92","author":"Mehta","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.104080_bib0013","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s40120-019-0127-2","article-title":"Real-world characterization of dimethyl fumarate-related gastrointestinal events in multiple sclerosis: management strategies to improve persistence on treatment and patient outcomes","volume":"8","author":"Min","year":"2019","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2022.104080_bib0014","unstructured":"Multiple Sclerosis International Federation, 2020. Atlas of MS \u20133rd Edition. https:\/\/www.atlasofms.org\/map\/global\/epidemiology\/number-of-people-with-ms (accessed 13 December 2021)."},{"key":"10.1016\/j.msard.2022.104080_bib0015","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/PPA.S118107","article-title":"An evaluation of adherence in patients with multiple sclerosis newly initiating treatment with a self-injectable or an oral disease-modifying drug","volume":"11","author":"Munsell","year":"2017","journal-title":"Patient Prefer Adherence"},{"issue":"1","key":"10.1016\/j.msard.2022.104080_bib0016","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12883-020-01830-0","article-title":"Real-world adherence to, and persistence with, once- and twice-daily oral disease-modifying drugs in patients with multiple sclerosis: a systematic review and meta-analysis","volume":"20","author":"Nicholas","year":"2020","journal-title":"BMC Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.104080_bib0017","first-page":"859","article-title":"Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriasis, psoriatic arthritis, and ankylosing spondylitis","volume":"23","author":"Rubin","year":"2017","journal-title":"J. Manag. Care Spec. Pharm."},{"issue":"8","key":"10.1016\/j.msard.2022.104080_bib0018","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1007\/s00415-020-09848-7","article-title":"Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population","volume":"267","author":"Sabin","year":"2020","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104080_bib0019","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s11657-018-0487-8","article-title":"Effect of a patient-support program on once-daily teriparatide adherence and persistence in the Japan Fracture Observational Study (JFOS)","volume":"13","author":"Sato","year":"2018","journal-title":"Arch. Osteoporos."},{"key":"10.1016\/j.msard.2022.104080_bib0020","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.msard.2018.05.007","article-title":"Real-life persistence and tolerability with dimethyl fumarate","volume":"24","author":"Sejbaek","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"1","key":"10.1016\/j.msard.2022.104080_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/10463356.2009.11883750","article-title":"Patient support services & patient satisfaction: can increased use of these services increase patient satisfaction?","volume":"24","author":"Wolcott","year":"2009","journal-title":"Oncol. Issues"},{"issue":"1","key":"10.1016\/j.msard.2022.104080_bib0022","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000593","article-title":"Impact of a structured patient support program on adherence and persistence in basal insulin therapy for type 2 diabetes","volume":"6","author":"Zhou","year":"2018","journal-title":"BMJ Open Diabetes Res. Care"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005880?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822005880?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:06:43Z","timestamp":1761901603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822005880"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":22,"alternative-id":["S2211034822005880"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104080","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adherence and discontinuation rates in patients on Tecfidera\u2122 (dimethyl fumarate): Long-term Canadian experience from the Biogen ONE\u2122 support program","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104080"}}